MedImmune Announces Winners of First European Cancer Research Abstract Competition

CAMBRIDGE, England, November 23 - Today MedImmune announced the winners of its European research abstract
competition which highlights the work of tomorrow's budding scientific
leaders in cancer research. Students and postdoctoral fellows from across
Europe were invited to submit abstracts on cancer research as part of a
competition sponsored by MedImmune, AstraZeneca's global biologics unit that
has a research facility in Cambridge, the United Kingdom.

First prize of GBP2,000 was awarded to Nicole Simonavicius, a PhD student
at The Institute of Cancer Research, London, UK for her research into the
role of the tumour pericyte receptor endosialin in angiogensis. "Winning this
competition is a great honour. Gaining such positive feedback from leading
experts has confirmed my commitment to scientific research," said Nicole. "I
am grateful to MedImmune for giving me the opportunity to present my research
- it is encouraging to see a research-focused company supporting the next
generation of scientists."

Second and third prizes of GBP1,000 and GBP500 were awarded to Eva
Schlecker, a PhD student at The German Cancer Research Centre, Heidelberg,
Germany, and Roberta Burden, a scientist at Queen's University Belfast,
Northern Ireland.

"It is encouraging to see the high calibre of scientific research that
went into the submissions we received," said Professor Volker Schirrmacher,
one of the competition's judges and retired Head of the Division of Cellular
Immunology at The German Cancer Research Centre, Heidelberg, Germany. "Their
research could pave the way for further understanding of tumour
microenvironment and could potentially help in the development of new
therapies in the fight against cancer."

"MedImmune is committed to fostering the development of the next
generation of leading scientists focused on improving human health. One of
our primary objectives at MedImmune is to promote and advance health and
science education, and this competition provides us with the opportunity to
acknowledge committed and talented researchers pursuing science degrees and
postdoctoral research in the field of oncology." said Klaus Bosslet, Vice
President of Research, Oncology, Cambridge. "We were impressed with the
standard of work delivered and congratulate all of the ten finalists for
getting this far. The students and scientists represented embody the future
of exciting cancer research and we at MedImmune are privileged to play a part
in their careers by providing some recognition for their hard work."

The competition was open to graduate students and postdoctoral fellows in
Europe with ten finalists shortlisted to present their research to an expert
panel of judges including Professor Gillian Murphy, Department of Oncology,
University of Cambridge; Professor Volker Schirrmacher, retired Head of the
Division of Cellular Immunology at The German Cancer Research Centre,
Heidelberg, Germany; and two senior MedImmune representatives. The three
winners were announced at the awards ceremony in Cambridge University's
historic Peterhouse College following evaluation of their presentations on
the basis of scientific merit, innovation and delivery.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE:
AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is
headquartered in Gaithersburg, Maryland. With an advancing pipeline of
promising candidates, we aim to be the next revolutionary force in
biotechnology by delivering life-changing products, industry-leading
performance, and a tireless commitment to improving patient health. For more
information, visit MedImmune's website at www.medimmune.com.

Media Contacts: MedImmune, Sidoney Atsé, Phone: +1-240-205-4891, Email: AtseS at MedImmune.com ; OgilvyHealthPR, Lucy Rispin, Phone: +44(0)778-991-4901 / +44(0)207108-6078, Email: lucy.rispin at ohpr.com .